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ABSTRACT 
 
THE BENEFITS OF YOGA THERAPY  
FOR HEART FAILURE  
PATIENTS 
by 
Paula R. Pullen 
 
STATEMENT OF THE PROBLEM 
 
The number of patients living with heart failure (HF) is on the rise. Yoga 
has been found to improve physical and psychological parameters amongst 
healthy individuals. The effects of yoga on HF patients are unknown. The 
purpose of this study was to examine the effects of yoga on cardio-vascular 
endurance [functional capacity (FC)], flexibility, inflammatory markers, and quality 
of life (QoL) on medically stable HF patients.  
METHOD 
Forty HF patients with compensated systolic or diastolic HF participated in 
the study. A randomized control design created two groups, yoga (N=21). and 
control (N=19).The treatment intervention consisted of 16-yoga sessions 
conducted bi-weekly (YG) vs. standard medical care (control- CG) for two 
months. All participants were asked to follow a home walk program. Pre- and 
post-study measurements included a treadmill stress test to peak exertion, 
flexibility (FLEX), girth, interleukin-6 (IL-6), c- reactive protein (CRP), and extra-
cellular dismutase (EC-SOD). Quality of life was assessed by the Minnesota 
Living with Heart Failure Questionnaire (MLwHFQ).
  
RESULTS 
Forty patients were randomized to YG (N=21) or CG (N=19). The results 
were significant for favorable changes in the YG as compared to the CG for 
flexibility (P=0.012), treadmill time (P=0.002), ~VO2peak (P=0.003), and all 
biomarkers (IL-6, CRP, and EC-SOD) of inflammation. Within the YG, pre- to 
post- test scores for the total and physical sub- scale of the MLwHFQ were 
significant (P=0.02 and P<0.001).  
CONCLUSIONS 
Yoga therapy offered additional benefits to the standard medical care of 
HF patients by improving QoL, exercise capacity, FLEX, and biomarkers of 
inflammation.
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CHAPTER 1 
 A REVIEW OF HEART FAILURE, EXERCISE AND YOGA 
 
INTRODUCTION 
The number of patients living with heart failure (HF) has been increasing, 
especially among the economically disadvantaged. Once established, symptoms 
of the disease may be minimized by optimal medical therapy, but it is rarely 
cured. Heart failure is a chronic disease, imposing a substantial clinical and 
economic impact on health care. According to the American Heart Association’s 
(AHA) 2008 statistical update, the U.S. prevalence of HF in adults was 
approximately 5.3 million in 2005 (5). Six years after a myocardial infarction (MI) 
the risk of developing HF for both men and women is one in five (84). The 
lifetime risk of HF occurring without an antecedent MI is one in nine for men and 
one in six for women (84). The incidence of HF is greater in men, until after age 
80 years when more women have the diagnosis, likely due to the higher life 
expectancy of women (84). Sudden cardiac death occurs at six to nine times the 
rate of the general population when HF is the diagnosis. According to the AHA, 
the estimated direct and indirect cost of HF in the United States for 2008 was 
$34.8 billion (5). 
Hypertension (HTN) is a common risk factor for HF with 75% of all HF 
cases having HTN as an antecedent diagnosis. The lifetime risk of HF doubles
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for people with blood pressure greater than 160/90mm Hg compared to those 
with blood pressure less than 140/90mm Hg (82). There are insufficient data 
available to determine relative risk for persons with a systolic blood pressure 
between 140 and 160mm Hg. According to a study conducted in Minnesota, the 
incidence of HF has not declined during the past two decades; survival after 
onset has increased overall, with less improvement among women and elderly 
persons (110). Increased survival may be due to improved medications and 
treatment alternatives that have evolved during the past couple of decades. 
Similarly, improved HF survival, likely due to improved treatment options, may be 
responsible for the increasing numbers of people with advanced chronic heart 
failure. The European Society of Cardiology published a position statement in 
2007 that defines the characteristics and treatment options for advanced chronic 
HF (92).   
One study that looked at the predictors of HF among women with coronary 
artery disease (CAD) found that diabetes was the strongest risk factor (17).The 
prevalence of diabetes is increasing among older persons with HF, and diabetes 
is a significant independent risk factor for death in these individuals. Mayo Clinic 
researchers found that the odds of having diabetes for those first diagnosed with 
HF in 1999 was nearly four times higher than for those diagnosed 20 years 
earlier (101). 
Heart failure patients experience multiple symptoms including dyspnea, 
exercise intolerance, fatigue, pain, and clinical depression, which significantly 
reduce their quality of life (QoL) (103, 128). These symptoms limit functional 
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capacity in patients with both systolic and diastolic heart failure (27). The 
incidence, morbidity, and mortality of HF remain elevated, despite effective 
medications and increased treatment options (99). However, studies support that 
interventions aimed at treating chronic symptoms of HF may improve QoL and 
lead to an improvement in overall health-related outcomes (128). 
Age is a risk factor for developing HF since incidence doubles 
approximately every 10 years of life (38). The number of people living with HF is 
also on the rise, which places an increasing burden on the Medicare system, 
according to a recent report from Duke University researchers (110). This large 
incidence of HF makes the investigation of the role of alternative therapies and 
primary prevention imperative. The addition of nontraditional treatment modalities 
may lead to better management of HF, with improved symptoms and QoL.  
 In addition to the pharmacologic treatment of HF, exercise rehabilitation 
programs improve exercise capacity in cardiac patients (50). Among 
unconventional forms of mind/body exercise, yoga has gained immense 
popularity (76) and appears to provide overall and specific benefit for cardiac 
patients (15, 50, 115). Currently, hundreds of medical centers in the United 
States offer yoga classes to their community members and patients. One of the 
reasons for yoga’s widespread appeal is that it may be adapted to a range of 
physical fitness levels. A suitably trained yoga therapist can modify postures and 
techniques to meet individual patient needs. Despite its emerging popularity as a 
form of exercise, only one study provides pilot data on whether the addition of 
yoga therapy improves symptoms or health-related quality of life exclusively in 
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patients with compensated heart failure (107). No other studies were found in the 
medical literature that examined the effect of yoga on individuals with HF. 
Yoga is an ancient form of mind-body therapy that combines specific 
physical postures, or asanas, with breathing techniques called pranayama and 
meditation, dhyana, to create a sense of well-being (51). Asanas range from 
simple to complex, combined with controlled breathing. Pranayama involves a 
variety of breathing exercises including; slow, deep inspiration, relaxation of the 
abdominal muscles and the diaphragm, followed by controlled, slow exhalation, 
involving conscious contraction of the abdominal muscles. A yoga session 
typically includes a period of relaxation and/or meditation to induce a calm state 
of mind. An improvement in baroreflex sensitivity, a reduction in heart rate 
variability, and a decreased catecholamine response to hypoxia and hypercapnia 
have all been implicated as possible mechanisms by which yoga may be 
beneficial in healthy individuals (13, 57, 85).  
Pro-inflammatory markers have been associated with unfavorable 
cardiovascular outcomes in HF (104). The focus of the present study was on the 
effect of yoga on biomarkers of inflammation and vascular elasticity, specifically 
Interleukin-6 (IL-6), C-reactive protein (CRP), and extracellular superoxide 
dismutase (EC-SOD). Elevated levels of IL-6 and CRP have been associated 
adversely with HF and EC-SOD activity has been correlated with endothelium-
mediated, flow-dependent vasodilatation (28, 80). Measuring biomarkers in 
conjunction with functional capacity (FC) could provide a basis of objective 
measures of Qol in HF patients. 
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A REVIEW OF HEART FAILURE 
 Heart failure defined. The definition of HF includes the inability of the 
heart to provide adequate blood supply to meet the metabolic demands of body 
organs and systems, or to do so only at abnormally high ventricular filling 
pressures (44). Heart failure ultimately results in organ hypoperfusion and 
venous congestion. Symptoms include fatigue, bilateral peripheral edema, 
orthopnea, and dyspnea during exertion, which may progress to occurring at rest. 
The increased discomfort during exertion begins a negative feedback loop that 
results in a decreased capacity for exercise. Interestingly, exercise capacity does 
not correlate well with ejection fraction or cardiac output (CO) (36). This 
phenomenon may be due a combination of effects between peripheral and 
neurohumoral factors that relate to the body’s response to decreased blood flow 
rather than initial impairment of oxygen extraction capability, cellular 
mitochondrial size and enzyme availability (35). The progression of HF, in the 
absence of physical training, leads to a worsening of the condition and its 
symptoms that spiral downward to an eventual deterioration of peripheral oxygen 
extraction mechanisms. The etiology of heart failure is eloquently described by 
Jaski (68) as: 
 ―…the cumulative outcome of all insults to the heart over time associated with 
changes in the peripheral vasculature. As patients survive manifestations of 
acute cardiovascular disease, late progression to heart failure becomes more 
common secondary to chronic ventricular enlargement and remodeling.‖ (pg 3) 
 
Hemodynamics. The medical presentation of HF is an abnormally low 
CO, which results from a variety of underlying conditions. Cardiac output (CO) is 
defined as:  
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CO=SV x HR (SV= stroke volume, HR = heart rate) 
Generally, HR issues are acute and can be treated promptly. Stroke volume is 
the component most often compromised with HF. There are four main 
determinates of low SV: preload (end-diastolic volume), contractility (end- systolic 
volume), afterload and the presence of regurgitant flow. Preload is the same as 
ventricular filling. When preload is low due to hypovolemia (low blood volume) 
the cause is usually due to something other than HF (e.g., dehydration or blood 
loss) (72). 
 Heart failure can result from either a reduction in preload or an increase in 
afterload. Reduced preload is the physiological state that occurs when the 
ventricle cannot fill properly despite a normal circulating blood volume, which 
leads to a reduced SV. A reduction in preload is most commonly caused by 
ventricular stiffness, pericardial constriction, or mitral valve stenosis. A less 
common cause of a reduced preload is the presence of an intracardiac mass 
(73). A state of reduced CO results in a decreased volume of blood being ejected 
to the peripheral circulation. Common causes of poor myocardial contraction 
include myocardial infarction, myocardial ischemia, and myocarditis, but 
infiltrative diseases are a rare cause of poor contractility (72). Reduced preload, 
from a prolapsed valve, interventricular or interatrial septal wall defect, may result 
in the backflow of blood. Left untreated, any of these conditions may result in 
irreversible HF.  
  Afterload is a term used to describe the resistance that must be overcome 
in order to eject blood from the ventricles. Increased afterload impairs ventricular 
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ejection and SV. Hypertension and aortic valve stenosis are common causes of 
abnormally high afterload. A chronic increase in afterload can lead to a 
hypertrophic cardiomyopathy, in which the heart muscle is thickened due to 
myocyte hypertrophy. In all of these circumstances, the flow of blood to the heart 
is inadequate, and HF eventually results (122). 
Two types of HF (diastolic and systolic) are distinguishable based on 
muscle fiber physiology. Myocytes, muscle cells of the heart contract during 
systole and relax during diastole. Heart failure can be a result of systolic 
dysfunction, diastolic dysfunction or some degree of both. Systolic dysfunction 
decreases contraction and diastolic failure impairs relaxation of the ventricles.  
Diastolic failure creates a stiff chamber that does not allow a normal amount of 
blood into the ventricles resulting in a decrease in preload (27).The body 
compensates for this by increasing the filling pressure. Examining a chest x-ray 
alone would not differentiate between systolic dysfunction and diastolic 
dysfunction as both conditions result in an enlarged silhouette of the heart. To 
distinguish between the two conditions an echocardiogram is necessary to 
examine the thickness of the ventricular wall since diastolic HF results in 
hypertrophy (thickening) of the heart. The typical cause of diastolic dysfunction is 
a history of long-standing systemic hypertension. Hypertension precedes 75% of 
all heart failure cases, which underscores the importance of early diagnosis and 
treatment of high blood pressure (82).  
Systolic HF results from a chronic volume overload that eventually dilates 
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the ventricle due to a process called remodeling. Remodeling describes changes 
in the shape or size of the heart that occur in response to prolonged, chronically 
increased pressure (afterload) or volume (preload). Another primary etiology of 
systolic HF is a history of a large or multiple myocardial infarctions. Risk 
reduction for systolic HF is the same as coronary artery disease (CAD), as 
myocardial infarction is the main cause of systolic HF (4).  
Physiology. The normal heart meets the demands of circulation based on 
three control mechanisms that vary in response time. Most immediately, 
contraction to contraction, the heart adjusts to preload (venous return) and after 
load (arterial resistance) based on feedback from the myocardial fiber’s stretch-
dependent mechanisms. The Frank-Starling relationship, contraction strength of 
the myocardial fibers is a function of fiber length at the end of diastole (ventricular 
filling), explains why short-term changes in ventricular blood volume immediately 
effect HR and contraction strength. Ejection fraction (EF) represents the percent 
of blood ejected from the ventricles, as a function of the amount of blood ejected 
per contraction at  the end of systole (stroke volume) divided by the end diastolic 
volume (EDV; the amount of blood in the ventricles at the end of diastole. At rest 
the normal physiological range for EF is >55% and it is a poor indicator of the 
heart’s ability to contract (72). 
The second mechanism involves biochemical processes that take longer 
to affect myocardial contraction. These pathways involve extracellular signals 
that initiate a cascade of intracellular reactions that, ultimately, influence 
individual myocytes and their contractile properties. Increased hemodynamic 
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demands may originate from exercise, emotions, digestion, or illness, to name 
just a few of the potential stimuli. Various physiological and psychological stimuli 
effect changes in ion pumps, ion channels, and exchanges that regulate the 
inotropic (contractile) aspects of the myocardium (73). The degree of inotropy 
refers to biochemical substances, endogenous to the body or prescribed 
medications, that affect the force of muscle contraction. For example, myocardial 
infarction may decrease the inotropic state causing a decrease in CO and in turn 
an increase HR and the potential for ventricular arrhythmias (122).  
The third and most complex mechanism involves growth abnormalities 
that change gene expression within the cardiac cells in response to circulatory 
changes. Molecular changes take longer to occur and are due to chemical 
signals that change a diseased heart, contributing to remodeling of the 
myocardium and the chronic sequale that defines HF (73). 
Treatment. Recently, there have been significant advances in the 
medical, surgical, pharmacological and assistive device management of HF. 
Despite these advances in treatment, one-third of all HF patients require 
hospitalization annually for exacerbation of their condition (5). Up to 30% of these 
patients require re-hospitalization for HF exacerbation less than three months 
after their first admission (110). Similar to several of the more aggressive 
cancers, the one-year mortality rate for patients with severe HF approaches 40% 
(5). The long-term prognosis is better for patients with less advanced HF; 
however, they still experience considerable morbidity, deterioration in functional 
status and decreased QoL (72). 
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Heart failure encompasses a collection of medical issues including high 
mortality, frequent hospitalizations, decreased QoL, a complicated therapeutic 
regimen and progressively worsening symptoms that limit exercise tolerance and 
pulmonary function. As a result, HF has become the focus of a growing body of 
research necessitating practice guidelines to keep HF treatment uniform among 
physicians (92). The guidelines emphasize that HF is a syndrome with many 
different etiologies and a variety of clinical presentations and symptoms.  
Heart failure may be due to damage from a single large MI or multiple 
smaller MIs. Etiologies may also include uncontrolled hypertension, diabetes, 
pulmonary hypertension, vascular stiffness, impaired renal-sodium handling, 
heart disease or dysfunction, infectious diseases, genetic predisposition and 
chronic drug or alcohol induced cardiomyopathy. The diagnosis of idiopathic 
cardiomyopathy is used when the etiology is unknown or due to multiple 
precipitating conditions. 
Approximately one third of all HF cases are cured by medical diagnosis 
and treatment. According to the Heart Failure Association of the European 
Society of Cardiology, two thirds of all HF patients are stabilized or advance to 
chronic HF (92). Medications currently recommended for the routine treatment of 
HF include angiotensin-converting enzyme inhibitors, or angiotensin receptor 
blockers, β-blockers and diuretics. Successful treatment of HF depends on 
severity, patient adherence to prescribed medications and compliance with 
lifestyle modifications that help minimize symptoms and may deter worsening of 
the disease. Early identification, primary and/or secondary prevention are critical 
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interventions that can minimize HF progression and complications (24, 44). 
Increased survival usually leads to comorbid conditions, such as renal failure or 
atherosclerosis, which complicate the treatment of HF patients. 
Psychosocial issues Comorbidities of the HF diagnosis often include 
psychological distress, reduced social functioning, and diminished QoL (10). This 
is not surprising, given that HF is associated with increased consequences of 
morbidity and mortality. These psychosocial factors precipitate hospital 
admissions in one third to one-half of patients with HF (24). Psychosocial issues 
can influence physiological outcomes in several ways. Serum catecholamine 
levels increase in the presence of uncontrollable stress, leading to deleterious 
effects of both cardiac and immune functions (33). There are other psychosocial 
factors, such as coping styles that influence the health behaviors of an individual. 
For example, denial can take the form of avoiding the reality of the severity of the 
illness leading to decreased compliance with prescribed treatments and behavior 
modification recommendations.  In HF, a few of the psychological contributors 
that play a role in adverse disease-related events may include depression, 
anxiety, and coping styles. Depression has been shown to increase cardiac 
events and overall mortality in patients with HF, even after controlling for other 
factors such as age, gender, New York Heart Association (NYHA) class, ejection 
fraction and serum B-type natriuretic peptide (BNP) levels (1, 63).  The NYHA 
functional classification system describes HF based on severity of HF symptoms 
(Table 1) (63).  
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TABLE 1. New York Heart Association (NYHA) Heart Failure  
Classification Scale 
 
 
 
 
 
 
Depression also plays a role in high readmission rates for patients with HF 
(60). Younger, chronically ill, disabled patients and elderly patients with major 
depression have been studied and found to have poor medical treatment 
compliance (23).  Therefore, it is possible that noncompliance with treatment 
regimens may be a major factor that precipitates re-admission for HF patients 
(87). 
 The diagnosis of depression is common for HF patients, occurring in 25% 
of patients. In addition, almost half have symptoms consistent with dysthymia, a 
milder form of clinical depression (60). Identifying and treating HF patients’ 
psychological issues in an accurate and timely manner may considerably 
increase their levels of functioning, leading to an improvement in physical health 
status (70, 78). Murberg and Furze (95) evaluated the long-term effects of 
depression on mortality risk among HF patients over a six-year period. 
Symptoms of depression were found to be a significant predictor of mortality. The 
remaining question, regarding mortality and depression, is whether treatment of 
depression reduces future risk or decreases morbidity (29). Yoga has been found 
NYHA Class Symptoms 
Class I No symptoms 
Class II Symptoms with moderate activity 
Class III Symptoms with light activity 
Class IV Symptoms at rest 
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to improve ratings of depression and may have a beneficial effect on heart 
patients (75). 
Anxiety is a condition that frequently presents in conjunction with 
depression. Patients with HF often experience considerable anxiety due to the 
physical symptoms of dyspnea, poor exercise tolerance, and concern regarding 
poor prognosis. Social, financial difficulty and the affects of their disease on 
family and work status, likely contribute to escalating anxieties for the HF patient. 
Mental stress is clinically relevant since it can negatively affect 
sympathetic nerve activity, regional blood flow and endothelium-mediated muscle 
vasodilatation of patients with HF (93, 111). Stress can cause an increase in HR, 
which has a negative effect on coronary artery perfusion by decreasing the 
duration of diastole; therefore, lowering myocardial oxygen delivery time. 
Tachycardia reduces the supply of oxygen to the heart, while increasing 
myocardial oxygen demand. This can create a downward spiraling effect, where 
patients become increasingly concerned about their physical state, which feeds 
back to increased anxiety and lower CO. Concerns about physical capability and 
anxiety about taking part in physical activities may also interfere with cardiac 
rehabilitation attempts. The possible pathways of chronic stress and the 
mechanisms involved were reviewed by Innes et al. (64) (figure 1).  
Chronic and debilitating illnesses such as HF may lead to stress that 
prompts the patient to seek a variety of coping strategies (126). Coping is defined 
as cognitive or behavioral attempts to either avoid a stressful situation or actively 
do something to alter or deal with the situation (91). The general definition of 
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coping style is the way in which the individual responds to stressful encounters. 
Individuals cope with negative or stressful life events in different ways that 
 
 
  
 
 
 
 
 
 
 
 
FIGURE 1- From: Pathological Sequellae of Chronic Stress: Possible Pathways. 
 CVD indicates cardiovascular disease; E indicates epinephrine; HPA indicates 
hypothalamic pituitary axis; IGF indicates insulin-like growth factor; IRS indicates insulin 
resistance syndrome; NE indicates norepinephrine (64).  
 
potentially can affect their physical and psychological well-being (47). Coping 
styles mediate between stressful life events and possible consequences such as 
depression and anxiety, which influence mortality in HF patients. In a study 
examining the association between coping styles and mortality in patients with 
HF, 119 outpatients were assessed on six subscales of the COPE inventory (94). 
A lower score on the proactive types of coping styles, and a higher score on the 
negative types of coping skills were significantly associated with increased 
morbidity and mortality, even when disease severity, gender, and age were 
controlled for using multivariate analysis (102). 
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Despite the difficulties of living with HF and the apparent success of 
educational programs following myocardial infarction, it is only recently that 
clinicians have begun to pay more attention to the psychosocial issues of HF. 
Some authors now suggest that interventions, which target the psychosocial 
factors involved in HF, may improve therapeutic compliance, reduce concomitant 
stressors and lead to an improvement in health-related quality of life (26). 
 
QUALITY OF LIFE 
Quality of life is an important factor when studying the effects of 
interventions in patients with HF, and numerous studies have evaluated the 
effects of various interventions on health related QoL in the HF population      
(52, 48). The accuracy of specific health related QoL measures in HF patients is 
an important consideration for research and clinical applications (30, 45). 
One such study examined the relationships between exercise capacity, 
QoL, and different ways of assessing functional capacity in HF patients (62). 
Thirty-six patients with stable symptomatic HF and confirmed left ventricular 
dysfunction had their exercise capacity measured using three different methods: 
maximal treadmill stress test, self-paced hall walk, and home based pedometer.  
The researchers found that the different methods did not yield comparable 
results in their correlation to QoL and hemodynamic measures (non-invasive CO 
and left calf skeletal muscle blood flow). Home-based activity, as measured by 
pedometer step count, correlated well with QoL and calf blood flow. Interestingly, 
the corridor walk and treadmill test correlated with each other and not with QoL 
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or hemodynamic measures. The author suggested that pedometer scores might 
provide a more reliable indicator of the patient’s own perception of their physical 
fitness. The patients with greater calf muscle blood flow likely had a better QoL 
because they were able to be more active. The fact that the pedometer scores 
were not related to the laboratory based exercise test supports the view that they 
measure different and complementary aspects of exercise capacity. 
Quality of life may improve with interventions such as home-based walking 
programs. One preliminary study examined the effects of a home walk program 
on total sleep time, physical function and QoL in older women with NYHA class II 
and III diastolic heart failure (55). Patients were randomized to either a 12-week 
home-based walking intervention (n=13) or education-only program (control, 
n=10). Between-group differences were not found in women in either the 
intervention or the control groups regarding any of the outcome variables. 
Outcomes were compared within each group at baseline and at 12 weeks. 
Intervention-group patients had improvement in total sleep time (P<0.01) and 
heart failure-related QoL (P<0.05), however, depressive symptoms were not 
significantly decreased (P<0.07). Women randomized to the control group had no 
change in any of the outcome measures. Their preliminary findings suggest that 
a progressive walking program may improve total sleep time and QoL in older 
women with diastolic HF. Larger studies might evaluate the long-term benefits of 
a walking program on sleep patterns, QoL, and psychological function in this 
population. 
In summary, QoL for the HF patient is a phenomenon influenced by 
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multiple psychological and physical components. Morbidity and mortality may be 
influenced in a positive manner by implementing alternative treatment strategies 
in addition to standard medical care. For example, improving a patient’s coping 
strategy or providing supervised exercise instruction to improve Qol and 
decrease medical costs (Figure 2). 
 
FIGURE 2- The burden of heart failure. 
 
HEART FAILURE AND EXERCISE 
Cardiac rehabilitation. Prevention of heart failure by lowering cardiac risk 
factors and treating the metabolic precursors of heart disease is the ideal 
treatment strategy for potential cardiac patients (6). However, for those patients 
that already have a HF diagnosis, cardiac rehabilitation programs offer a second 
chance to adopt positive lifestyle behaviors. Cardiac rehabilitation with an 
exercise prescription is an important component in the management of patients 
with HF, cardiac exertional symptoms, and exercise performance (32). 
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Improvements in peak oxygen consumption, CO and vascular function are a few 
of the clinical benefits gained by attending cardiac rehabilitation programs (125). 
The majority of patients referred to cardiac rehabilitation programs have a 
diagnosis of CAD. To attend a cardiac rehabilitation program a physician’s 
referral is required. Typically, patients undergo an entry evaluation to measure 
their exercise capacity and to formulate an individualized exercise prescription. 
Supervised exercise training may take place three days per week for three to 12 
months. Telemetry monitored electrocardiograms (ECGs) are utilized to establish 
a baseline during the first few weeks of exercise. The duration of continuous 
EKG monitoring depends on individual risk stratification and hemodynamic 
responses to exercise during training. Improved quality of life and 
cardiorespiratory function for HF patients have been reported after participating 
in aerobic exercise for 12 months (74). Currently, HF patients may not receive 
insurance reimbursement for cardiac rehabilitation. 
Unfortunately, the logistics and practical aspects of attending a formal 
cardiac rehabilitation program prevent many patients from complying with a 
physician’s recommendation or referral to attend a hospital based cardiac 
rehabilitation program. Financial, social, and family issues are among some of 
the obstacles of compliance. Cooper et al. (34) examined cardiac rehabilitation 
attendance and patient’s beliefs toward cardiac rehabilitation. Patients’ beliefs 
accounted for 65% of the variance found. Four barriers were identified and they 
differed significantly between attendees and nonattendees. The barriers were 
identified as perceived necessity, exercise concerns, practical barriers, and 
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personal suitability. In a similar study, interviews of post-MI patients were 
thematically analyzed which led to discovering that the determinants of cardiac 
rehabilitation relevance and adherence was influenced by financial, family, and 
social situations regardless of the encouragement they received toward attending 
the program. The researchers concluded that it might be unrealistic to anticipate 
100% attendance in these programs.   
Walking interventions. Adherence to any exercise program is difficult; 
factors that have been found to interfere in attendance to cardiac rehabilitation 
programs include financial, social, and family concerns (58). Based on the 
assumption that a large segment of the cardiac patient population will not attend 
supervised exercise sessions, home exercise may be a reasonable alternative 
pursuit. Ideally, a qualified health care professional prescribes exercise and 
follows the heart failure patient in a cardiac rehabilitation setting. For those who 
cannot attend formal programs, a practical and safe alternative may be a home 
or community based walking or exercise program. In this circumstance, a 
physician or Clinical Exercise Physiologist could develop the exercise 
prescription on an individual basis for home implementation. Home-based 
walking programs have been reported to be reasonably safe for HF patients and 
measures can be implemented to facilitate adherence (46).  
Number of steps walked at home, as measured by pedometers worn by 
HF patients (N=84), were found to predict survival better than the laboratory-
based exercise test in a study that examined the relationship between daily 
activity levels and long-term prognosis (127). Pedometer measured steps have 
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predicted exercise adherence and mortality in HF patients (49). The use of 
pedometers to study the activity level and exercise capability of HF patients, 
initially reported by Cowley et al. (36) in 1991, correlated poorly with treadmill 
stress test performance.  However, in a second study where CO was measured 
indirectly using the Fick principle, CO correlated significantly (p< 0.001) with 
customary activity as assessed by the measurement of pedometer steps (35). 
Conversely, the relationship between treadmill stress test performance and CO 
was poor (P=0.245). The authors concluded that CO is a reliable index for 
determining patients’ exercise capacity when walking speed is self-directed, but 
not when undergoing laboratory treadmill tests.   
Adherence to exercise is clinically important and relevant to the 
assessment of the effectiveness of interventions and their outcomes. Recently, 
the validity of pedometers for measuring exercise adherence during a 12-month 
home-based walking program in HF patients was studied (7). The validity of 
pedometer use in HF patients was determined by finding that patients who 
increased their steps at home by at least 10% (defined as adherers), also had 
significant increases in their functional status, as measured by the 6-minute walk 
and peak oxygen consumption tests. Considering the previous studies, the 
addition of pedometers to measure home activity and to encourage adherence to 
the home walk program seems reasonable. 
Exercise benefits. Exercise is recommended and appears to be safe and 
beneficial for stable, well-compensated HF patients, although mortality benefits 
have not yet been determined (120). Compensated HF refers to the condition 
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where many of the accompanying symptoms of HF (e.g., fluid retention and 
pulmonary edema) have been stabilized or improved due to medical intervention. 
Studies show that exercise programs that are individually tailored to HF 
participants are well tolerated and yield positive adaptations on a muscular, 
metabolic and neurohormonal level (71, 77).  
A relatively large (N=94) randomized trial that examined the effects of a 
one-year exercise intervention on HF patients (NYHA II- IV) concluded that long-
term exercise training improved FC and QoL in chronic HF patients (9). 
Additionally, patients with left ventricular dysfunction decreased their symptoms, 
improved neurohormonal function and lowered vasoconstrictive hormones by 
participating in a physical conditioning program. Typically, HF patients gradually 
lose their ability to engage in physical exercise, especially activities involving 
dynamic large muscle mass movement, in response to symptoms of fatigue and 
dyspnea. To reverse the cycle of further exercise intolerance and peripheral 
muscle atrophy, the HF patient may benefit from medical guidance regarding 
safe exercise progression (31). Further benefits regarding muscle structure, 
endothelial function, catecholamine release, and peripheral oxygen extraction 
have been reported (39). The Committee on Exercise, Rehabilitation, and 
Prevention of the American Heart Association recommends that medical 
insurance companies support exercise training programs that follow their 
guidelines based on the existing evidence that HF patients benefit from exercise 
(106). 
Exercise prescription. The American College of Sports Medicine 
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(ACSM) published guidelines that address some of the specifics of exercise 
prescription and physical conditioning for the HF patient (129).  According to the 
ACSM, HF patients considered for exercise training should be clinically stable 
with an exercise capacity of at least 3 METs and under the care of a physician. 
The exercise prescription should be based on a symptom-limited stress test 
(treadmill or cycle ergometer). The exercise intensity is derived from a target 
heart rate (THR) that corresponds with 40 to 70% of peak oxygen consumption. 
The guidelines recommend that the exercise duration is between 20-40 minutes 
per session at a frequency of three to seven days per week. Additional medical 
test information, such as echocardiograms and heart catherization results, add to 
the formulation of the exercise prescription. Longer warm-up and cool-down 
periods (10-15 minutes each) and avoidance of isometric exercise are advised. 
Initial exercise training time is increased gradually at intervals of two to six 
minutes, with one to two minutes of rest between bouts in order to stay below 
symptom thresholds. Exercise intensity should not provoke a worsening of 
dyspnea or other symptoms. Coincidentally, HF patients may have impaired 
chronotropic response making heart rate response to exercise a less reliable 
indicator of intensity. The ACSM guidelines conclude that perceived exertion and 
dyspnea may be better indicators of exercise intensity than heart rate alone for 
HF patients.  
Moderate continuous verses aerobic interval training was studied in a 
group of postinfarction HF patients to examine which type of exercise yields 
greater benefits (131). Twenty-seven patients were randomized to either exercise 
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treatment or control group. The exercise treatment groups participated in a 
supervised exercise program, three times a week for 12 weeks. Maximal oxygen 
consumption improved significantly more in the aerobic interval training group 
than the continuous exercise group and was associated with reverse left 
ventricular remodeling. In the clinical setting, all of these recommendations are 
useful to consider when formulating an exercise prescription for a patient with 
HF.  
YOGA 
Yoga defined .Yoga is a system of physical and mental disciplines 
designed to foster the practitioner’s mental and physical health (61). Yoga 
typically includes a triad of exercises; physical postures known as asanas 
(denoting a static physical position); breathing exercise called pranayama, and 
some form of relaxation or meditation. Hatha yoga is the generic term for the 
practice of the physical postures (asanas) intended to improve physical health by 
balancing strength and flexibility. The philosophical aim of yoga is to be 
comfortable enough to practice meditation without physical or mental 
disturbance. The word Hatha is a combination of two Sanskrit words Ha and Tha; 
meaning sun and moon. Many styles of yoga have developed, ranging from a 
focus on alignment of the body while holding static postures (for example, 
Iyengar style) (67), to a more dynamic and strenuous sequence of postures 
referred to as Vinyasa, Ashtanga or Power Yoga (18).  
The popularity of yoga has increased tremendously over the past two 
decades in the United States. It has evolved from an eccentric and 
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misunderstood practice to a mainstream training available in most public and 
corporate fitness facilities. Approximately 15 million Americans have engaged in 
a yoga practice at least once for either wellness or specific health conditions 
(112). Yoga classes are offered in 75% of all health clubs in the United States 
and held in yoga studios, community centers, hospitals, colleges, schools, pre-
schools, and senior citizen centers (76). There is some debate regarding whether 
or not the western version of yoga and its commercialization is consistent with 
the basic philosophical tenets of yoga (133). Some of the concern is on emphasis 
of Hatha yoga, the physical postures, over the many other components of yoga. 
The other aspects of yoga include the practice of abstinences (yamas), 
observances (niyamas), breath control (pranayama), sense withdrawal 
(pratyahara), concentration (dharana), contemplation (dhyana) and self-
realization (samadi). The entire practice is known as the eight limbs of yoga. 
Yoga therapy research. Claims regarding the health benefits of yoga are 
emerging in the scientific literature. In the past, most yoga research was 
conducted without the rigorous methods expected by the western scientific 
community. Currently, western standards and practices, include randomization 
and control groups, are being applied to yoga research around the world. The 
emerging research is legitimizing age old claims regarding the positive effects of 
yoga on stress reduction, anxiety, depression and a variety of other medical 
disorders including the management of hypertension (96, 116). 
Studies of yoga therapy involving healthy subjects found that practicing 
various relaxing and calming yoga asanas blunted the normal physiologic 
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response to artificially induced physical stress, as measured by changes in HR 
recovery, HR variability, blood pressure, and respiratory rate (85, 12). Anxiety 
levels were lowered significantly in the yoga treatment group when 104 medical 
students were randomized to either yoga therapy or usual medical care (88). 
Anxiety was assessed utilizing the State Trait Anxiety Scale. Subjects in another 
study benefited from yoga therapy with a reduction in depressive symptoms 
according to the Beck Depression Inventory and subjective improvement in their 
sense of well being, feeling of relaxation, concentration, self-confidence, 
interpersonal relationships, and irritability levels, have also been reported 
following a yoga intervention (109). 
The physiological effects of a regular yoga practice combined with 
breathing exercises lead to improved muscle strength, flexibility, cardiovascular 
endurance, and pulmonary function in human subjects. One study included 
fitness testing before and after an eight-week course of yoga training in 
previously sedentary individuals. The average improvements reported were 31% 
for muscle strength, 57% for muscle endurance, flexibility 88%, and aerobic 
capacity 7% (8).  
The contribution of yoga to cardiovascular endurance and its metabolic 
requirement has been examined by researchers and is critical to consider before 
making recommendations for HF patients. A comparison of the metabolic 
requirements of a 32 minute Hatha yoga routine to 32 minutes of treadmill 
walking at 4.0mph was investigated (42). Ten healthy subjects 38- 47 years of 
age achieved an energy expenditure of 4.1 METs for the yoga routine, compared 
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with 5.4 METs required for the treadmill walking. In comparison, a similar study 
that measured the oxygen requirements of a more dynamic form of yoga routine 
(Vinyasa style) reported a metabolic demand of 6.7 METs (25). Clearly, the 
metabolic requirements vary considerably based on the type of yoga practiced.  
Randomized controlled trials of yoga therapy in hypertensive individuals 
have demonstrated 15mmHg reductions of systolic blood pressure and 10mmHg 
reductions of diastolic blood pressure (117). They also reported a reduction in 
subjective symptoms of stress and anxiety with yoga. Improvement of such 
magnitude is comparable to what many hypertensive medications achieve. 
 Scientific studies that examined the mechanisms of how yoga works are 
also emerging in the medical literature. Several reviews have pooled yoga 
research studies and summarized their findings in an effort to examine the role of 
yoga on health (64, 65, 108). One of these review articles looked at 70 studies 
that met specific inclusion criteria between 1970 and 2004 (64). The selected 
studies were all concerned with the role of yoga and risk-reduction of the insulin 
resistance or metabolic syndrome and cardiovascular disease. Benefits of a yoga 
intervention were hypothesized to be synonymous with improved cardiovascular 
risk profiles, summarized by two physiological pathways (figure 3). 
The mechanisms by which the practice of yoga can improve the insulin 
resistance syndrome related abnormalities and cardiovascular disease related 
outcomes are thought to involve two pathways. First, yoga may lead to down 
regulation of the sympathoadrenal system and hypothalamic pituitary adrenal 
axis, thereby shifting autonomic regulation towards the parasympathetic system 
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(Figure 3, Pathway 1). In effect, yoga may cause decreased perceived 
psychosocial stress and levels of depression, improved mood and sleep patterns, 
improved insulin sensitivity and glucose metabolism, reduced cholesterol and 
triglyceride levels and subsequent weight loss in the form of reduced visceral fat  
(79). Second, by stimulating the vagus nerve directly, yoga may promote 
additional parasympathetic activation thus leading to decreased heart rate and 
blood pressure, improved heart rate variability, and similar metabolic and 
psychological benefits as seen in pathway 2 (Figure 3, Pathway 2). 
 
 
 
FIGURE 3- From: Hypothesized Pathways by Which Yoga Intervention May Enhance 
 Cardiovascular Risk Profiles (64)  
 
 The effect of yoga on brachial artery reactivity in patients with coronary 
artery disease (CAD) or at high risk for CAD was studied in a 6-week pilot study 
(115). Impaired endothelial function is one of the mechanisms related to an 
increased risk of MI. Interestingly, the yoga intervention significantly improved 
brachial artery reactivity in the participants that had known CAD and had little 
association with the high risk group (119). 
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Collectively, these anthropometric, psychological and metabolic changes 
may lead to improved coagulation and inflammatory profiles. Yoga, therefore, 
may promote increased fibrinolysis, decreased free radial production and 
oxidative stress and improved endothelial function (107, 118). Understanding that 
atherosclerosis is an inflammatory process and cardiovascular events are in part 
dependent on endothelial function, lends physiological support to the literature 
showing yoga can reduce progression while improving management and clinical 
endpoints of atherosclerosis, hypertension, cardiovascular disease and risk 
factor reduction (40, 53, 89, 115). 
Breathing research. The practice of yoga often includes breath 
awareness and specific breathing exercises called pranayama. Patients with HF 
who regularly practice breathing exercises derive an improvement in symptoms 
of dyspnea (22, 90). Breathing exercises teach patients to facilitate diaphragmatic 
breathing and inhibit excessive accessory muscle use, leading to decreased 
breathing work and energy expenditure. This is especially important to patients 
with pulmonary diseases. One randomized study of pranayama-type breathing 
exercises slowed the resting respiratory rate from 15 breaths per minute to six 
per minute. Fifteen HF patients had significant improvements in, peak oxygen 
consumption ventilation/perfusion mismatching, exercise tolerance, and 
perceptions of dyspnea after one month of therapy (16). Other studies using 
similar techniques for longer periods have shown improvements in chemoreflex 
activation, allowing for a greater tolerance to hypoxia and hypercapnia, and 
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increased arterial baroreflex sensitivity (14, 121). The latter is frequently impaired 
in HF and is associated with adverse prognosis. 
The benefits of pranayama-type breathing exercises occur in healthy 
participants as well. In normal subjects, a combination of yoga therapy, including 
pranayama, for 12-15 weeks in a total of 347 volunteers was found to improve 
pulmonary function with increased forced vital capacity (FVC), forced expiratory 
ventilation in the first second of exhalation (FEV1), and peak expiratory flow rate 
(19).The effect of a daily yoga practice on pulmonary function in 60 healthy 
women (age 17-28) was significant after 12 weeks, as compared to the first six 
weeks of practice (132).  
The pranayama component of any yoga study is difficult to isolate since 
breathing instruction and awareness is often a part of the physical practice of 
yoga. The benefits of hatha yoga training alone might be controlled for if one arm 
of a study consisted of breath training alone. Theoretically, benefits beyond 
breath training alone could be contributed to the physical aspects of yoga. 
 
INFLAMMATORY MARKERS AND ENDOTHELIAL DYSFUNCTION 
 A review by Braunwald in 2008, suggests that endothelial dysfunction is 
one of the hallmarks of cardiovascular disease (20).  Endothelial cells line the 
inner most layer of the circulatory vessels and are responsible for the regulation 
of vascular tone. The production of nitric oxide (NO) takes place locally in the 
endothelial layer and is ultimately necessary for vasodilatation to occur. The nitric 
oxide production pathway involves several local substances that are referred to 
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as biomarkers. Many of the biomarkers have been studied in an effort to 
determine if they have prognostic, predictive or preventive value as clinical tools 
(figure 4) (59, 113).  
 Biomarkers are also examined in an effort to discover if complementary or 
alternative therapies for HF may exist since pharmacological therapies do not 
completely repair endothelial function. The increased availability of NO in the 
endocardium is thought to be the most important factor in restoring endothelial 
function (41). In contrast, exercise training corrects impaired circulatory vessel 
dilation by restoring levels of NO. Impaired endothelial-dependent vasorelaxation 
has been identified as an independent cardiovascular risk factor and a prognostic 
marker of cardiovascular disease (3, 97). Regular physical exercise is known to 
lower the risk of heart disease and the pro-inflammatory markers associated with 
unfavorable cardiovascular outcomes for HF patients. The reduction of 
inflammatory markers has also been reported to improve the oxidative capacity 
of skeletal muscle in HF patients which resulted in an increased exercise 
capacity (56). Three biomarkers, IL-6, CRP and EC-SOD were selected as 
indicators of a reduction in vascular inflammation (decreased IL-6 and CRP) 
and/or an improvement in vascular reactivity (increased EC-SOD) in HF patients.  
Interleukin-6 is a low molecular weight pro- inflammatory cytokine that has 
a variety of related immune and inflammatory properties. Interleukin-6 is secreted 
by T-cells, macrophages, and by the smooth muscle cells of most blood vessels. 
The chronic over-production of IL-6 in the circulatory system makes it useful as a 
predictor of cardiovascular mortality and an important prognostic indicator for HF 
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FIGURE 4- From: Factors influencing the bioavailability of nitric oxide (NO) in the endothelium, 
arrows define stimulating pathways, while bars define inhibitory pathway. See text for further details. 
AMPK, AMP-activated protein kinase; CaMKII, Ca2+-calmodulin-dependent protein kinase II; TK, 
tyrosine kinase; HDL, high density lipoprotein; PI3K, phosphatidylinositol 3-kinase;ADMA, 
asymmetric dimethylarginine; SOD, super oxide dismutase; O2-, superoxide anion; MAPk, mitogen 
activated protein kinase; eNOS, endothelial nitric oxide synthase; AGE, advanced glycosylation end 
products; NO, nitric oxide; GTP, guanosine tri-phosphate; sGC, soluble guanosine cyclase; cGMP, 
cyclic guanylyl monophosphate; [Ca2+], Ca2+ concentration; PKB, protein kinase B (Akt); HSP 90, 
heat shock protein 90; H2O2, hydrogen peroxide (59).  
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patients (124). C-reactive protein is an acute phase plasma protein whose levels 
rise dramatically during inflammatory reactions (2). Elevated levels of one or 
more of these biomarkers indicate an adverse association with HF and CAD (37, 
123).  
Extra cellular-superoxide dismutase is an enzyme with important 
antioxidant properties that catalyze the dismutation of superoxide (an isoform of 
oxygen, known to damage smooth muscle cells) into oxygen and hydrogen 
peroxide leading to an increase in NO levels (80). In addition, EC-SOD 
expression may be down-regulated in the presence of elevated homocysteine 
(98). This may explain why increased EC-SOD activity in the NO pathway 
correlates with improved endothelium-mediated, flow-dependent vasodilatation. 
Heart failure patients are known to have an impaired vasodilatory response 
which could be related to a reduction in EC-SOD and the presence of 
inflammatory cytokines.  
A recent review of exercise training and its effect on inflammatory markers 
in HF patients concluded that abnormal levels of inflammatory markers are 
associated with left ventricular dysfunction, pulmonary edema, left-ventricular 
remodeling, and cardiomyopathy (97). Furthermore, they reported that routine 
exercise decreased these biomarkers (IL-6 and TNFα) and were associated with 
lowering oxidative stress, morbidity, hospitalization, and mortality. 
Debate still exists regarding the most advantageous type, frequency and 
exercise intensity to prescribe for HF patients. To optimize the effects of exercise 
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on endothelial function and peak oxygen consumption, aerobic interval training 
may yield greater benefits than moderate continuous aerobic exercise (131). The 
authors suggest that the characteristic hypoperfusion of heart failure and 
resultant oxidative stress are the initial stimulators of the chronic inflammatory 
response. What remains to be answered is whether the reduction of the 
inflammatory response leads to improved morbidity and mortality in the HF 
population. Toward that end a large multi center study called the Heart Failure 
Action Trial (HF-ACTION) is underway and may yield important results regarding 
exercise, morbidity and mortality for HF patients (130). Preliminary results from 
the 2008 AHA national meeting, indicated that HF patients who exercised for two 
hours a week decreased mortality and heart failure hospitalization by 7% (100). 
A recent and novel pilot study looked at the effect of aerobic training on 
vasodilatory capacity and proinflammatory markers in HF patients that had 
undergone heart transplant surgery eight weeks prior (105).  After 12-weeks of 
aerobic training in a cardiac rehabilitation setting, inflammatory markers [CRP, IL-
6, TNFα and soluble intercellular adhesion molecule-1 (sICAM-1)] remained the 
same in the exercise group and increased significantly in the control group. The 
exercise group also increased their treadmill test time significantly (52%) with a 
concurrent improvement in vasodilatation of a calf artery (22%). Neither of these 
parameters improved for the control group. Previous studies reported that 
vasodilatory changes are also due to systemic factors which would have resulted 
in improved forearm blood flow (83, 114). The exercise intervention in the heart 
transplant study did not include upper body training and there was a lack of 
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improvement in forearm blood flow. Future studies might include an upper body 
training regimen and contrast it with lower body exercise to examine this issue. 
Also, glucocorticoids and cyclosporine medications are known to cause 
endothelial dysfunction, a confounding issue when heart transplant subjects are 
involved (130). 
Pilot study. Studies on both humans and rats have found that regular 
exercise maintains the absolute relaxation function found in the arterial vessels 
which may contribute to an increase in FC. Individuals with HF that exercised at 
moderate levels of intensity improved their endothelial function. The practice of 
yoga includes several of the components that have been found to benefit HF 
patients. 
Research on stress reduction, breath training, and physical activity has 
been associated with a reduction in peripheral markers of inflammation and 
improved exercise tolerance in HF patients. This led to a pilot investigation of 
yoga as an exercise that might yield similar, if not greater benefits for HF 
patients. The research consisted of biweekly yoga classes at the hospital’s 
Vascular Research Laboratory. Interleukin-6, CRP and EC-SOD were selected 
as biomarkers to measure the effects of yoga on the endothelium-mediated, flow-
dependent vasodilatation in HF patients in a pilot study. The pilot study also 
examined the effect of yoga on HF patients’ FC, flexibility and QoL (107). In a 
predominantly African-American (AA), out-patient cohort, measurements 
included a treadmill test to determine peak oxygen consumption, inflammatory 
markers and self-reported psychological well-being via the Minnesota Living with 
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Heart Failure Questionnaire (MLwHFQ). Twenty patients with NYHA class I-III 
symptoms of HF met inclusion criteria and were enrolled. All patients were 
medically stable, for at least six months prior to the study. The cohort included 
one patient with a diagnosis of diastolic HF who completed the study and was not 
included in any of the statistical analysis. Half the patients were randomized to 
the yoga treatment and the other half were randomized to usual medical care. 
The yoga group patients were placed in a program involving 60 minutes of yoga 
instruction and therapy twice a week, for an 8-week period. Measured variables 
included HR, blood pressure, flexibility, waist/hip ratio, and a ramp protocol 
treadmill test (TM) to peak oxygen consumption (i.e., symptom limited maximum) 
with a 12-lead continuously monitored ECG. Significant improvements for all 
inflammatory biomarkers (IL-6, CRP, and EC-SOD) and FC occurred in the yoga 
group (n=9) after 8-weeks of yoga training compared with the control group 
(n=10).  
The patients who participated in the pilot study were encouraged by their 
improvements. The yoga group reported an increased ability in tasks of daily 
living and decreased symptoms from their HF which was congruent with the 
objective measures. Owing to the small sample size of the pilot study, further 
investigation with a larger number of patients was conducted. 
 The benefits of yoga, relaxation and yogic breathing on CAD risk factors 
have been documented in healthy and at risk subjects (11, 54). Heart failure 
therapy has improved resulting in the increased survival of HF patients. However, 
the medical management of HF remains challenging. Cardiovascular morbidity 
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and mortality remain high for HF patients, inviting the investigation of alternative 
therapies in an effort to improve QoL.  
Exercise is routinely prescribed to cardiac patients for its multiple benefits, 
including improvement of inflammatory markers and vascular reactivity. Heart 
failure patients typically have comorbities that prevent them from participating in 
traditional exercise. The lower metabolic demand of yoga is flexible, ranging from 
chair based to continuous flow, presenting an option for HF patients to participate 
in an exercise intervention with a sense of mastery, rather than difficulty. Yoga 
therapy may also be a safe and novel exercise alternative for HF patients if the 
metabolic and cardiovascular benefits are found to be similar to traditional 
exercise modalities.
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CHAPTER 2 
THE BENEFITS OF YOGA THERAPY FOR HEART FAILURE PATIENTS 
 
Heart failure (HF) is one of the most prevalent chronic illnesses of modern 
society with profound clinical and economic impact (29, 33). The manifestations 
of the disease significantly reduce quality of life (QoL) among those who live with 
HF (4, 7, 53, 54). In patients with systolic and/or diastolic HF, the symptoms of 
the disease usually limit functional capacity (36, 46). Previous studies have 
supported interventions aimed at treating the chronic symptoms of HF, QoL, and 
overall health-related outcomes (52). Physical exercise in the form of yoga has 
gained immense popularity (23) and may be beneficial in cardiac rehabilitation 
(11, 48). Despite yoga’s widespread appeal, there is little data on whether the 
addition of yoga therapy improves symptoms or health-related QoL in patients 
with compensated, chronic HF (39).  
Yoga combines structured physical exercises with breathing techniques 
and meditation to stimulate a sense of well-being.  The breathing, relaxation and 
meditation components may lead to an improvement in baroreflex sensitivity and 
a reduction in heart rate variability (9, 10). A variety of beneficial effects for 
patients with cardiovascular disease has been reported. For example, studies 
have reported an improvement in lipid profiles (17), blood pressure (42) 
psychological well-being (26), and even regression of atherosclerosis when
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combined with dietary and other life-style modifications (34, 35, 49). The clinical 
application of the previous studies may be limited by the lack of control groups, 
and the varied style, intensity, and duration of the yoga interventions. Pro-
inflammatory markers have been associated with unfavorable cardiovascular 
outcomes in HF (38). Elevated levels of interleukin-6 (IL-6) and C - reactive 
protein (CRP) has been adversely associated with HF (12, 56); Extra-cellular 
super-oxide dismutase (EC-SOD) activity has been correlated with endothelium-
mediated, flow-dependent vasodilatation (27). A randomized control group 
design was utilized to study the effects of an 8-week, low intensity, yoga program 
on the peak cardiovascular capacity, and biomarkers of inflammation, and QoL in 
patients with HF. 
The present study was a continuation of the pilot study, with minor 
changes (40). In the second cohort, patients with diastolic HF were included, 
because similar changes with exercise training have been reported in the 
scientific literature (46). The aim of the present study was to further substantiate 
the findings of the pilot study and possibly illuminate additional effects by 
increasing the number of subjects in the control and treatment groups.  
Hypothesis. Stable HF patients who participate in an 8-week program of 
yoga therapy classes will improve their exercise capacity, inflammatory markers 
of cardiovascular function and QoL measures as compared to a control group of 
HF patients that receive standard medical therapy alone.  
METHODS 
 Patient selection.  Forty patients were recruited prospectively from the 
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out-patient cardiology clinic at Grady Memorial Hospital in Atlanta, Georgia. All 
patients had systolic or diastolic HF of ischemic or nonischemic etiology. Patients 
were randomized to a supervised hospital-based yoga therapy group (YG) or a 
control group (CG), in addition to standard medical care. Patients were included 
if they had: 1) systolic or diastolic heart failure  2) New York Heart Association 
(NYHA) class I-III; 3) were able to walk without assistance; and 4) were on stable 
medical therapy for heart failure at least three months prior to enrollment. 
Patients were excluded if they: 1) had significant co-morbidities with a life 
expectancy < 6 months; 2) were pregnant or breast feeding; 3) were unable to 
attend yoga sessions twice a week or 4) were currently addicted to alcohol or 
drugs. The study was approved by the Institutional Review Board (077-2004) at 
Emory University and by the Institutional Review Board of Georgia State 
University (H09015). Patients that were eligible for participation in the study were 
appropriately screened and enrolled after informed consent (Appendix A). 
Pre- test and post- test assessment. Patients were scheduled for initial 
assessment at the Vascular Laboratory located at Grady Healthcare System’s 
main hospital in Atlanta, Georgia. Pre-testing and subsequent appointments 
followed in a timely fashion (Figure 1).  
 
Screen & 
Recruit                      Pre-test                    Yoga sessions          Post-test 
 
 0               Week 1               Weeks 2 - 9               Weeks 9- 10 
FIGURE 5- Time line for the study. 
Cardiovascular parameters included resting systolic blood pressure in 
right and left arms, 12 lead EKG, and treadmill stress test. The sit and reach test 
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for flexibility (best of three), girth measurements for the waist/hip ratio, the 
Minnesota Living with Heart Failure Questionnaire (MLwHFQ), and venipuncture 
for serum biomarkers (IL-6, CRP, and EC-SOD) were also obtained during the 
assessment visits. Both groups received HF patient education, and a brochure 
with instructions for following a home walk progression. Documentation of current 
exercise behavior and exercise history was recorded during the initial visit and 
upon completion of the study. Investigators responsible for assessment of 
outcomes were blinded to the treatment assignment. 
Yoga therapy. One hour yoga sessions were conducted twice a week in a 
quiet room located within Emory University’s Vascular Laboratory. Patients 
randomized to yoga were given a yoga mat and strap for their personal use. 
Blood pressure and pulse were recorded before and after each class. Patients 
attended a total of 16 supervised sessions over an 8-10 week period. During 
each session, subjects completed the following:  a five-minute warm-up phase 
including breathing exercises (pranayama), a 40-minute period of standing 
and/or seated yoga postures (Asanas) and finally, a 15-minute relaxation phase. 
Upon completion of the first four classes, patients were given a handout of the 18 
yoga postures taught during class (Appendix B). The YG patients were asked to 
practice at home with a goal of three yoga sessions per week. The yoga sessions 
were conducted by a Registered Yoga Teacher (RYT-Yoga Alliance®) certified 
by the American College of Sports Medicine (ACSM; Registered Clinical Exercise 
Physiologist®), with over twenty years of experience in the field of cardiac 
rehabilitation. The yoga asanas for this study included traditional hatha yoga 
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postures including, combinations of forward and backward bends, twists and 
balance poses. Modifications were made on an individual basis, according to 
individual medical and orthopedic limitations. Chairs were utilized for patients 
unable to get up from the floor unassisted, and the wall was incorporated during 
the standing balance postures, as needed. 
Breathing exercises consisted of deep inhalation and exhalation in a 1:1 
ratio, without breath retention. Inhalation was taught to begin with sequential 
involvement of the abdomen, lower chest, and then upper chest, with the same 
sequence in reverse, during exhalation. Meditation and relaxation was performed 
in a supine or seated position according to the patient’s comfort level. 
Exercise/fitness testing. All patients underwent a graded exercise test 
(GXT) at baseline and at the conclusion of the two month study period to 
determine exercise capacity (Marquette Electronics, Inc. Model: Case12 EKG 
and Marquette 2000 treadmill). Maximum oxygen consumption was estimated 
based on the work load at peak exertion utilizing the American College of Sports 
Medicine’s standard formula for treadmill walking (55): 
VO2 (mL/kg/min) = 0.1 (speed) + 1.8 (speed) (fractional grade) + 3.5 mL/kg/min 
 A one minute per stage, ramp protocol treadmill test was utilized for all pre and 
post treadmill tests (Table 2).  
Additional baseline and post test measurements included EKG, blood 
pressure, flexibility (sit and reach test), and girth (waist and hip). Waist 
circumference was measured at the narrowest part of the torso and hip 
circumference was obtained 
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Table 2. Heart Failure Ramp Protocol 
 
Time 
(Min.) MPH Grade ~METS 
1 1 0 1.8 
2 1.5 0 2.2 
3 2 0 2.7 
4 2.5 0 3.1 
5 3 0 3.5 
6 3 1 3.9 
7 3 2 4.3 
8 3 3 4.7 
9 3 4 5.1 
10 3 5 5.6 
11 3 6 6 
12 3 7 6.4 
13 3 8 6.8 
14 3 9 7.2 
15 3 10 7.7 
16 3 11 8.1 
17 3 12 8.5 
18 3.5 12 9 
 
at the maximum extension of the buttocks, as described in the Anthropometric 
Standardization Reference Manual (28). 
Measurement of soluble levels of IL-6, hsCRP, and EC-SOD. 
Venipuncture was performed at baseline and at the conclusion of the study. 
Plasma samples were centrifuged and stored at –80oC. An aliquot was drawn, 
and enzyme immunoassay (EIA – Cayman Chemical, Ann Arbor, Michigan) for 
serum IL-6, hsCRP, and EC-SOD was performed on each sample in triplicate. A 
total of 50 microliters of serum was used for analysis, and EIA was performed as 
previously described (21). The levels of total serum IL-6, hsCRP, and EC-SOD 
were determined on a plate reader at an optical density of 420 nm.  
Quality of life. Quality of life was assessed with the MLwHFQ (14). This 
disease-specific questionnaire is the most widely used and validated assessment 
of quality of life in patients with HF. The MLHFQ is composed of 21 questions 
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addressing physical function, symptoms of heart failure, and psychosocial issues. 
The participants completed the questionnaire at enrollment and again at the end 
of the study. A decrease of five points in total score after a specific intervention is 
regarded as clinically significant (41). 
Data analysis. Statistical analyses were conducted utilizing the Statistical 
Package for Social Sciences 16 (SPSS, Inc., Chicago Ill., USA). Means and 
standard deviations were computed for continuous variables, and t-test 
comparisons for within groups’ analyses of pre- and post-test findings were 
conducted. A one-way analysis of variance was conducted on all measured 
variables between groups for comparisons of pre-to post-test differences. 
Confounding factors were adjusted for at baseline.  
Success indicators were considered to be favorable changes in the 
treatment group, regarding inflammatory markers, ramp protocol treadmill test 
time to peak exertion in seconds, estimated peak oxygen consumption, flexibility, 
and QoL indicators that reached statistical significance (α<0.05), after the 16    
bi-weekly yoga sessions. 
 
RESULTS 
 
Demographics. Ninety-one patients were interviewed initially regarding 
participation in the study. Fifty-one patients did not meet various eligibility criteria 
or declined to participate. Forty patients (17 females, 23 males) enrolled in the 
study, ages ranged from 31-76 years. Twenty-one patients randomized to the YG 
and 19 randomized to the CG. Three YG patients did not complete the study and 
three CG patients did not return for post- testing. 
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There were no significant differences between the groups in age, EF, 
resting heart rate, blood pressure, body weight, body mass index, flexibility, 
treadmill test time, VO2peak, QoL scores, or biomarkers at baseline. Non-
ischemic HF was the dominant etiology based on clinical history (Table 3).  
 
TABLE 3.  Patients’ Baseline Clinical Characteristics 
Total number of patients (n=40) YOGA Group (n=21) Control Group (n=19) 
Age (years) 55.8 ±7.6 52.5±12.7  
Men/Women, n (%) 
BMI 
10 (47.6)/11 (52.4) 
35.7±10.1 
13 (68.4)/6 (31.6) 
32.6±9.5 
Etiology 
-Systolic Heart Failure, n (%) 
   Ischemic 
   Valvular 
   Non-Ischemic 
Diastolic Dysfunction, n (%) 
NYHA Class, n (%) 
7 (33.3) 2 (10.5) 
3 (14.3) 1 (5.3) 
10 (47.6) 
 
3 (14.3) 
12 (63.2) 
 
4 (21.1) 
I 
II 
III 
6 (28.6) 4 (21.1) 
8 (38.1) 8 (42.1) 
7 (33.3) 6 (31.6) 
Ejection fraction by TTE, Mean (SD) 31.2% (9.8)  27.1% (14) 
Medical History, n (%) 
CAD 8 (38.1) 6 (31.6) 
Diabetes 8 (38.1) 3 (15.8) 
Hypertension 20 (95.2) 18  (94.7) 
Current Smokers                                                                                      2 (9.5) 3 (15.8) 
Aldosterone Blockers 7 (33.3) 8 (42.1) 
ACEI/ARB 13/4 (61.9/19.0) 17/2 (89.5/10.5) 
Statins 15 (71.4) 12 (63.2) 
B-Blockers 20 (95.2) 19 (100.0) 
n=number, EF: ejection fraction, TTE: transthoracic echo, CAD: coronary artery disease 
 
 
Exercise testing. Pre to post- test differences between the groups were 
significant for treadmill time and VO2peak (P=0.002, P=0.003, Table 4). The YG 
increased their treadmill time by 22%, after the yoga intervention, while the CG’s 
time decreased by 5% (Table 4).  
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Table 4. Between Group Differences 
Test Yoga (YG) 
% change from Baseline 
Control (CG) 
% change from Baseline 
P Value for 
Difference 
Weight  
Flexibility 
Treadmill Time 
~VO2peak 
1.68↑ 
17.22↑ 
19.28↑ 
                    15.08↑ 
4.64↓ 
7.67↑ 
5.3↓ 
3.95↓ 
0.983 
0.012 
0.002 
0.003 
MLHFQ-T 
MLHFQ-P 
28.49↓ 
28.17↓ 
2.93↓ 
0.58↑ 
0.199 
0.128 
MLHFQ-E 
IL-6  
CRP  
EC- SOD  
31.93↓ 
18.82↓ 
24.49↓ 
18.67↑ 
3.45↑ 
1.61↑ 
2.46↓ 
1.1↓ 
0.425 
0.001 
0.001 
0.001 
    
IL-6: interleukin-6 (pg/ml); CRP: C-reactive protein (mg/l); Ec-SOD: extracellular superoxide dismutase 
(U/ml); Treadmill time in seconds; VO2peak: mL/kg
-1
/min
-1
; Oxygen consumption, MLHFQ: Minnesota  
living with heart failure questionnaire 
 
Soluble inflammatory markers. There were clinically significant within 
group improvements in the plasma serum levels of the three biomarkers for YG 
patients (Table 5). Interleukin- 6 decreased from a mean value of 19.6 ± 2.5 to 
16.0 ± 2.1mg/dl (P<0.001, N=18), CRP decreased from 2.4 ± 0.58 to 1.9 ± 0.4 
Mg/dl (P<0.001). Levels of EC-SOD increased from 509 ± 71.9 to 610 ± 86.2 
U/ml (P<0.001). Furthermore, between group comparisons from pre test 
to post test were significant for YG improvements (IL-6; P<0.001, CRP; P=0.001, 
EC-SOD; P<0.001; Table 4).  
Quality of life. There was a significant change from pre-test to post-test 
for the total scores and physical subscale scores for the MLwHFQ,  within the YG 
(Table 5). No significant changes were found in the paired samples analysis for 
the CG. Other significant improvements within the YG from pre- to post- test 
were for improved flexibility (P=0.002). 
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Table 5. Within Yoga Group Differences 
   
Parameter 
pre- post 
Time= 0 Months Time= 2 Months P- Value 
Time 0 vs. 
time 2-months 
 
Flexibility -1.4±5.6 0.29±4.5 0.002 
Treadmill Time 441±208 565±222 0.001 
VO2peak 15.3±5.1 18.4±5.6 0.001 
MLHFQ-T 41.55±21.82 30±15 0.02 
MLHFQ-P 18.6±10.8 13.6±6.8 0.034 
MLHFQ-E 7.8±4.6 5.4±5.4 0.192 
IL-6 (pg/ml) 19.6±2.5 15.9±2.1 0.001 
CRP (mg/l) 2.4±0.58 1.9±0.39 0.001 
EC- SOD (U/ml) 509.1±71.8 610.1±86.2 0.001 
 
Values are mean ± standard deviation; Flexibility in inches; IL-6: interleukin-6; CRP: C-reactive protein; Ec-
SOD: extracellular superoxide dismutase; Treadmill time in seconds; VO2peak: mL•kg
-1
•min
-1
; Oxygen 
consumption; MLHFQ: Minnesota living with heart failure questionnaire; T= total score; P= physical sub-
scale; E= emotional sub-scale. 
 
 
DISCUSSION 
 
Despite significant advances in medical and surgical management of HF,  
the one-year mortality rate for patients with advanced HF remains approximately 
35% (5).  Prognosis may be better in patients within the early stages of HF but, 
they continue to experience considerable symptoms, deterioration in functional 
status, and a poor QoL (6).  Psychosocial factors and reduced QoL contribute to 
recurrent HF exacerbations and hospitalizations (37, 57). The present study is 
unique in that there were no yoga studies in the medical literature that utilized a 
randomized control design while examining the clinical effects of yoga on HF 
patients. There is little data on the unconventional techniques of mind-body 
medicine specific to cardiac patients.  
   The addition of an organized program of yoga therapy for 8 weeks to 
standard medical treatment of HF led to an improvement in flexibility, exercise 
capacity, ~VO2peak, and reduced inflammatory markers. Mechanisms by which 
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yoga therapy may have improved the clinical parameters in this study are 
speculative at this time. In addition to hemodynamic derangements, an increased 
neuro-hormonal activation via the sympathetic nervous system and the renin-
angiotensin system has been implicated in the progression of HF (20, 43). 
Indeed, drugs such as beta-blockers and ACE-I/ARBs that block this neuro-
hormonal activation lead to a reduction in morbidity and mortality in patients with 
HF (1, 2).  Heart rate, blood pressure, and the respiratory rate interval are all 
influenced by input from both the parasympathetic and the sympathetic systems.   
Arterial baroreflex modulates vagal nerve traffic to the sino-atrial node.  In post 
myocardial infarction (MI) patients, it has been observed that if the vagal 
baroreflex is abnormal, there is an increased risk of fatal events due to 
ventricular tachycardia (24).  Furthermore, in patients with HF, the arterial 
baroreflex insensitivity may also lead to ventricular arrhythmias (25, 31). 
Combining yogic postures with breathing exercises and meditation attenuates 
sympathetic activation and could lead to a decrease in ventricular filling 
pressures. This may explain part of the improvement in exercise capacity that 
was found in this study (based on the significant improvement in treadmill time 
and estimated VO2peak in the yoga group as compared to the control group).  
Yoga postures, relaxation, and breathing practices may improve patient 
well-being and retard the pathogenic mechanisms observed in HF. Dyspnea in 
chronic HF results in muscle fatigue from decreased arterial CO2 (18). Dyspnea  
requires increased ventilatory effort, driven by sympathetic activation, 
predisposes to ventricular arrhythmias.  In addition to allowing for a 
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predominance of the parasympathetic state, yoga may also promote effective 
extraction of oxygen by peripheral tissues. When muscle is stretched, the O2 
consumption increases. Studies that examined the health related aspects of yoga 
found that an 8-week yoga training program increased muscular strength by 
31%, increased muscular endurance by 57%, increased flexibility by 88%, 
improved oxygen uptake by 7% and a reduction in cardiovascular risk in healthy 
adults (15, 50). These data appear to support the current study’s increase in 
exercise tolerance in the yoga treated group, as reflected by longer treadmill 
times and an increase in VO2max. Flexibility increased significantly in the current 
study which was anticipated since the sit and reach test is a replication of one of 
the yoga postures in the routine. It was encouraging to find that, despite their 
comorbities, age, and poor EF, the YG patients were able to improve their range 
of movement. 
Several studies of yoga treatment in hypertensive patients have 
demonstrated mean reductions of systolic and diastolic blood pressure of          
15 mmHg and 10 mmHg, respectively (32, 42). The insignificant blood pressure 
and heart rate changes in this cohort may have been influenced by medications,  
and the fluctuations in body weight noted throughout the study. 
In addition to the proposed mechanism of yoga’s ability to attenuate the 
derangements of the autonomic nervous system, and thereby improve 
symptoms, its effect on psychological well-being may be a benefit as well. Major 
depression occurs in 25% of patients with HF, and 50% report symptoms 
consistent with subclinical depression or dysthymia (19), which in turn affect 
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patient QoL and raise mortality (17).  Increased serum catecholamine levels due 
to stress cause deleterious effects on cardiac health and immune function  
(13, 22, 51).   
In this study, answers to the well-validated MLwHFQ indicated that 
patients who did yoga perceived it to be beneficial. Statistical significance was 
reached for total scores and for the physical improvement subscale which is 
congruent with a positive QoL effect. The emotional subscale failed to reach 
significance; possibly due to a few extraneous incidents that occurred to a couple 
of the YG participants during the study (one patient’s brother died unexpectedly 
and another’s husband was placed in intensive care).  
The yoga treatment patients reported an improved tolerance for the 
activities of daily living. Another important factor to consider is that modified yoga 
postures can be practiced safely by the disabled, the elderly, and by patients with 
chronic debilitating illnesses like arthritis and HF, compared to the conventional 
aerobic forms of exercise which can be demanding. There were no adverse 
outcomes in patients in the YG, and they tolerated this form of non-aerobic 
exercise quite well. Interestingly, compliance for the yoga sessions and testing 
appointments was 85% for both the treatment and control subjects. 
Increased levels of markers of inflammation such as IL-6 and CRP have 
been associated with higher mortality in cardiac patients (38). This data suggests  
that  yoga therapy may improve endothelial function by decreasing inflammation 
and oxidative stress at the level of vasculature reactivity. The levels of all three 
biomarkers improved after 8 weeks of yoga therapy compared to the CG. These 
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results are noteworthy: CRP decreased by 20% in the YG compared to 1.6% in 
the control group; IL-6 decreased by 22% in the YG compared to minimal change 
from baseline in the CG (Table 4).This is consistent with the effect cardiovascular 
exercise has on markers of inflammation (16). Both forms of activity may also 
improve endothelial function by increasing levels of Ec-SOD and NO activity     
(3, 47). Recently, a pilot study demonstrated that after six weeks of yoga 
participation, brachial artery reactivity improved only in the CAD patients, as 
opposed to individuals at risk of CAD (44). Thus, in patients with HF, yoga 
therapy may improve functional capacity and QoL by lowering sympathetic 
response to physical activity, leading to a reduction in cytokines and oxidative 
stress resulting in improved vascular reactivity. 
 Limitations. The exclusive reliance on markers of inflammation as 
improvement indicators of HF severity may not be ideal.  Additionally, estimations 
of peak aerobic capacity, rather than direct measurements of oxygen uptake 
were conducted (8).  Furthermore, to clarify that the improvements were specific 
to the yoga therapy, a standardized home exercise or cardiac rehabilitation 
program may have been a better control to compare than medical therapy.  
 Conclusion. This study of the effect of yoga on exercise capacity, 
inflammatory markers and QoL in patients with HF indicates that yoga may 
provide a beneficial adjunctive therapy and may be safely added to standard 
medical care under similar circumstances. Markers of inflammation such as IL-6, 
hsCRP, and EC-SOD showed a significant improvement with an 8-week yoga 
based program in patients with compensated systolic and diastolic HF. Larger 
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patient groups and longer term studies that control for physical activity are 
needed to further delineate the mechanisms of improvement that are unique to 
yoga. Future investigation with additional measurements of brachial artery 
reactivity, myocardial contractility, accelerometer recordings, depression 
inventories and symptom rating scales, in a head to head comparison with 
exercise therapy may further delineate the benefits and mechanisms of yoga 
therapy as an adjunct treatment of HF. In conclusion, yoga offered additional 
benefits to HF patients in regards to FLEXIBILITY, exercise capacity, 
inflammatory markers, increased precursors of NO, and QoL when compared to 
a group of HF patients that received standard medical therapy. 
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APPENDIXES 
APPENDIX A 
 
EMORY UNIVERSITY SCHOOL OF MEDICINE 
DIVISION OF CARDIOLOGY 
CONSENT TO BE A RESEARCH SUBJECT 
 
TITILE: The Effects of YOGA in Congestive Heart Failure 
INVESTIGATORS: Bobby V. Khan, MD PhD, Paula R. Pullen, M.Ed. 
INTRODUCTION/PURPOSE: 
You are being asked to volunteer to participate in a research study. Before 
agreeing to participate in this research study, read the following carefully and ask 
the study doctor any questions. Please take your time to make your decision. No 
guarantees or assurances can be made as to the result of the study. You have 
been asked to participate in this study because you have heart failure, a disease 
in which the heart cannot pump enough blood to meet the needs of the body. 
The research study will evaluate the effects of usual medical care (which will 
include heart failure education and home walk instruction) with or without 
supervised yoga sessions in people with heart failure. Several studies have 
shown that people with heart failure have higher amounts of depression and 
anxiety, as well as a lower quality of life, than people without heart failure. People 
with heart failure are also more likely to be hospitalized and have more difficulty 
doing their day to day activities due to failure, breathing difficulty, and weak 
muscles that their heart failure causes. 
Yoga is a form of structured physical exercises called asanas, combined with 
breathing exercises called pranayama, and relaxation techniques that is an 
increasingly popular type of fitness exercise for well being in the US. Several 
studies have found that healthy people who do yoga have lower amounts of 
depression and anxiety, as well as a better quality of life than people who don’t 
do yoga. In addition, they also have better muscle strength, endurance, and 
flexibility. Other studies have shown that people with heart failure who do yoga-
type breathing exercises or pranayama have less trouble breathing and more 
endurance. This study looks at whether adding a program of regular yoga 
practice to usual medical care offers any advantage over medical care alone in 
people with heart failure. There will be 120 volunteers participating in this study 
which takes place at Grady Health System. 
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PROCEDURES: This study takes 10 weeks to complete with an initial pre-test 
the first week, eight weeks of yoga session visits to the Vascular Lab, twice a 
week and a post-test after yoga sessions are completed. The sessions will 
consist of yoga classes lasting approximately one hour. You will need to wear 
comfortable clothing that allows you to bend and stretch. Eat a light breakfast at  
least 2 hours prior to your yoga class time and take all prescribed medications as  
usual. The screening pre-test and post-test visits and a total of 16 yoga session 
visits will all take place at the Vascular Research Lab on the second floor  
(C-Hall room 233) at Grady Health System. 
SCREENING AND PRE-TESTS: 
You will be asked to come to the Vascular Research Lab for two study visits, one 
at the start of the study and again at the end. You will be required to fast (nothing 
to eat or drink but water, for 12 hours) prior to each of these visits. At the first 
―screening visit‖ and pre-test visit, the study doctor will determine whether you 
are eligible to take part in the study. During this first visit the study doctor or staff 
will explain the study to you and answer any questions you may have. If you 
agree to take part in this study, you will sign a consent form. The study doctor will 
then ask you about your medical history, your health, recent medications 
changes and will examine you. There are several procedures that you will be 
asked to complete during the first study visit and the last. This will consist of a 
couple of questionnaires, some blood will be drawn, height, weight hip and waist 
measurements, blood pressures, electrocardiograms, treadmill exercise tests 
and a flexibility test. The treadmill test allows us to evaluate you r level of 
physical fitness. The treadmill will slowly increase in s peed and steepness with 
electrodes attached to your chest to evaluate your heart rate and rhythm and 
capacity for exercise. The electrodes will be attached using sticky pads and will 
be removed after the test is over. In addition, you may be asked to wear a small 
mask that fits over your mouth and nose so that we can monitor the amount of 
oxygen you are using. The study doctor or Exercise Physiologist will measure 
your blood pressure every 2 minutes during the exercise test. The exercise test 
will be stopped whenever you want or when the study doctor feels it is proper to 
do so. During this visit, a study doctor or staff will talk with you about things you 
can do to help yourself manage heart failure. At the end of Visit 1, you will be 
assigned by change (like drawing straws) to one of the following groups: 
Group1: Heart Failure Education and home walking instruction only 
You will be given a brochure today and instructions to guide your home walk 
program over the next 2 months. Use the recording section in the back of the 
brochure to track your progress. At the completion of the study, bring your That 
will complete your participation in the study. walking record back, in order to 
discuss your progress with the Exercise Physiologist. You will be contacted in 
about eight weeks to schedule your post-test visit will consist of the same tests 
and questionnaires as the pre-test visit.   
Group 2: Heart Failure, home walk instruction and Yoga sessions 
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You will receive the same home walk instruction as group 1 with the addition of 
attending the yoga classes two times per week for and eight week period. 
The classes will meet in the Vascular Research Lab for one hour and you will be 
asked to arrive about 10 minutes before the class begins in order to put on a 
single chest strap and wrist watch type of pulse monitor and for the study staff to 
take your blood pressure and weight at each visit. 
Run-In Period 
After the screening visit, volunteers who are eligible to take part in the study will 
first be asked to complete a 2-week run-in period. This will allow you to see for 
yourself if this study is for you and also allows the study doctors to identify and 
correct and problems that might keep you from participation in the study. You will 
be asked to complete at least 4 in hospital yoga sessions in 2 weeks. These 
sessions will involve learning how to do yoga. Volunteers who cannot compete all 
4 sessions will not be allowed to participate in the study. 
Study visits 
If you complete the run-in period and want to continue with the study, you will be 
asked to come to the Vascular Research Lab for your first official study visit or 
Visit 1. These include giving you information about limiting the amount of salt and 
fluid you use, as well as ways to make sure you take your medicines properly 
and things to watch out for that could make you feel worse due to your heart. You 
will be asked to bring your spouse, significant other, or a family member to this 
study visit so they can also receive information about taking care of heart failure. 
You and your family members/friends will also be invited to join weekly cooking 
classes for people with heart failure. 
Exercise treadmill test 
Upon completion of the yoga session visits you will be asked to complete an 
exercise treadmill test similar to the one you completed during the screening visit. 
You can stop the exercise test whenever you want to or when your study doctor 
feels that it is proper to do so. 
Physical Examination 
A study doctor will examine you during the first and last study visits. In addition, 
we will check your blood pressure, heart rate and weight during each visit. 
Blood Draw 
During both testing visits, we will draw approximately 1-2 teaspoons of blood 
from a vein in your hand or arm. These samples will be used to measure certain 
compounds in the blood that are often higher in people with heart failure. 
Pregnancy tests 
If you are a woman who can bear children we will ask you to complete a 
urine pregnancy test at the beginning and the end of the study. 
Yoga Sessions 
If you complete the pre tests and want to continue with the study, you will be 
assigned by chance to one of two groups during visit 1: Group 1(usual medical  
You will be asked to come to the hospital 2 times a week for the in-hospital yoga 
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sessions. These exercise sessions take place in the Vascular Research Lab at 
Grady Health System. During the last 6 weeks of the study you will be asked to 
add on one home based yoga session per week for the remaining six weeks of 
the study. You must complete at least 80% of the in-hospital yoga sessions 
during the eight week study (at least 13 sessions) in order to qualify for the post-
test visit. Every effort will be made to provide make-up classes in the event a 
yoga session is missed due to circumstances beyond your control. There will be 
an exercise physiologist/yoga teacher present at each in-hospital yoga session. 
Our exercise physiologist is trained in cardiac rehabilitation and yoga teaching. 
She can determine what yoga posture modifications are safe and monitor your 
response to the yoga. Your blood pressure, heart rate, and perceived exertion 
will be monitored while you are attending the yoga session and we will be able to 
help you if there are any medical problems during exercise. Your blood pressure 
and heart rate will be checked at the beginning and end of each yoga session. 
You may also be asked to wear a monitor on your chest and wrist to allow our 
exercise physiologist to monitor your heart rate while exercising. The exercising 
physiologist will use your heart rate, as well as your own feelings of how hard you 
are exercising, to adjust your yoga postures. You will also be given a logbook to 
record when you exercise or do the yoga series at home. The log will also 
include what type of exercise you did, for how long and how you felt. The 
exercise physiologist will collect these log books and review them with you. 
If you are hospitalized for a heart condition during the study, we may ask you to 
begin the study again, after you are medically cleared. 
Yoga asanas for this study consist of 18 exercises designed to increase 
muscle strength, muscle flexibility, balance and relaxation. Volunteers in 
Group 2 will receive a Yoga 4 Heart handout that describes each posture, a 
Yoga 4 Heart video to use as a reference. during the home sessions. 
Risks 
People with heart failure can usually perform gently yoga without significant 
difficulty. However, like any exercise program, there may be risks caused by the 
exertion of exercise. Common side effects include tiredness, shortness of breath 
and muscle soreness, especially during the first few weeks of exercise. Less 
commonly (1 in 100), you may have problems with chest pain or angina that 
makes you stop exercising. This usually happens only in people with blockages 
in their heart arteries. Rarely (less than 1 in 5000), you may experience severe 
chest pain, heart attack, worsening of your heart failure, or an abnormal heart 
rhythm that requires further treatment and possible admission to the hospital. 
Your exercise physiologist will monitor your progress during the in-hospital yoga 
sessions for your safety. She will also teach you how to monitor yourself while 
you do the home-based yoga. You should stop exercising immediately if you 
develop chest pain; lightheadedness, significant shortness of breath or other  
significant symptoms develop and report them promptly to the exercise 
physiologist. 
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Blood draws 
Blood samples will be collected during the first and last study visit. You may have 
discomfort, bruising, and /or bleeding at the site where the blood is taken. 
Localized blood clot formation and infections may occur but this is rare. We will 
place a small piece of gauze and a bandage over the site where blood is taken. 
There is a small chance of a reaction to the bandage that usually gets better 
once it is removed. 
Exercise Treadmill test 
You will be asked to undergo an exercise treadmill test to evaluate your level of 
fitness during the screening visit and at the completion of the study. A study 
doctor will monitor your progress and help safeguard against any potential 
problems. Risks of an exercise test include but are not limited to a 1 in 10,000 
risk of falls, heart attacks, or abnormal heart rhythms that may require further 
treatment. You should notify your study doctors immediately if you notice any 
discomfort or unusual symptoms during the study visit or at any time during the 
study. 
Benefits 
Taking part in this study may not benefit you directly, but we doctors may learn 
new things that will help future patients. 
Alternatives 
You do not have to participate in this research study or yoga sessions. The 
alternative to participating in this study is not to participate. 
Compensation 
We will arrange for emergency care if you are injured by this research, the study 
doctors, the Vascular Research Lab, Emory University, Georgia State University 
and the Grady Health System have not set aside funds to pay for this care or to 
compensate you if a mishap occurs. Lab tests, physician fees, and costs for the 
Vascular Research Lab will pay for procedures done during each of the study 
visits. Financial compensation for such things as medical care lost wages, 
disability or discomfort due to injury or illness is not routinely available. You will 
be financially responsible for any additional treatment that may be required after 
participating in this study. You will not, however, give up your legal rights by 
signing this form. If you believe you have been injured by this research, you 
should contact Dr. Bobby Khan (phone 404-616-4440) promptly. You may keep 
the yoga mat if you complete the entire study successfully. 
Confidentiality 
All information concerning you will be kept private. People other than those doing 
the study may look at both medical charts and study record. Agencies that make 
rules and policy about how research is done have the right to review these 
records So do agencies that pay for the study. Those with the right to look at your  
study records include: Georgia State University, Emory University, The 
Institutional Review Board, and the Grady Research Oversight Committee and 
the Clinical Trials office of Emory University. Records can also be opened by 
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court order. We will keep your records private to the extent allowed by law. We 
will do this even if outside review occurs. We will use a study number rather than 
your name on study record where we can. Your name and other facts that might 
point to you will not appear when we present this study or publish its results. 
People other than those doing the study may look at both medical charts and 
study 
records. Agencies and Emory departments and committees that make rules and 
policy about how research is done have the right to review these records. So do 
companies and agencies that pay for the study. The government agencies and 
units within Emory responsible for making sure that studies are conducted and 
handled correctly that may look at your study records in order to do this job 
include The Institutional Review Board of Emory University, The Research 
Oversight Committee at Grady Health System, the FDA and the Clinical Trials 
Office of Emory University. Companies and other groups that pay for studies and 
that are listed in consent and authorization documents also will have the right to 
look at your records. In addition, records can be opened by court order or 
produced in response to a subpoena or a request for production of documents. 
We will keep any records that we produce private to the extent we are required to 
do so by law. We will use a study number rather than your name on study 
records where we can. Your name and other facts that might point to you will not 
appear when we present this study or publish its results. Some tests and 
procedures that may be performed during this study by Emory Healthcare or 
other facilities or persons may not be looked at or read for any healthcare 
treatment or diagnostic purposes. The specific types of tests or procedures, if 
any, that fall within this category are listed below: none 
Contact Persons 
Call Dr. Bobby Khan if you have any questions about this study or if you think 
you may have been harmed from being in this study. Call Dr. Colleen DiIorio, 
Chair of the Emory University Institutional Review Board at 404-616-0720 if you 
have any questions about your rights as a participant in this research 
study. If you are a patient receiving care from the Grady Health System and you 
have a question about your rights as a Grady patient, you may contact Dr. Curtis 
Lewis, Senior Vice President for Medical Affairs for Grady Health System at 404-
616-4261.You may also contact the Georgia State University Office of Research 
Integrity (Susan Vogtner) at 404-413-3513. 
Voluntary Participation and Withdrawal 
Your participation is completely voluntary and you have the right to refuse to be 
in this study. You can stop at any time after giving your consent. This decision 
will not affect in any way your current or future medical care or any other benefit 
to which you are otherwise entitled. 
Consent 
The study doctor/investigator may stop you from taking part in this study at any 
time if they decide it is in your best interest, or if you do not follow study 
instructions. You will be given a copy of this consent to keep. 
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I have read and understand this entire consent for. All my questions have 
been answered. I volunteer to participate in this study.  
 
 
_________________________________ ____________________________ 
Signature of Volunteer Date and TIME 
 
 
_________________________________ 
Printed Name of Volunteer 
 
 
________________________________ _____________________________ 
Name of Person Obtaining Consent Date and TIME 
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